Stay updated with breaking news from Study Evaluating Protective Efficacy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
-- The study, a collaboration between Clover and the International Vaccine Institute, showed that a household contact was 84% less likely to get a SARS-CoV-2 infection when the infected household... | November 30, 2022
Clover's Recombinant Protein-based and Adjuvanted COVID-19 Vaccine), a global pivotal Phase 2/3 clinical trial evaluating the efficacy, safety and immunogenicity of SCB-2019 (CpG 1018/Alum), Clover's COVID-19 vaccine candidate. SPECTRA is a double-blind, randomized, controlled study of SCB-2019 (CpG 1018/Alum) administered in a two-dose regimen, 21 days apart. Global enrollment surpassed 29,000 adult and elderly participants resulting in one of the most ethnically diverse COVID-19 clinical trials conducted to date, including over 45% of participants from Asia, 45% from Latin America and th...